Myofascial Trigger Point Pain Clinical Trial
Official title:
Effects on Neuromuscular Function After Dry Needling in Myofascial Trigger Points in the Gastrocnemius Muscles: A Randomized Within-Participant Clinical Trial
NCT number | NCT04851743 |
Other study ID # | CBAS-2018-11B |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 10, 2021 |
Est. completion date | July 6, 2021 |
Verified date | September 2020 |
Source | Universitat Internacional de Catalunya |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Trigger points (TrPs) are a common musculoskeletal cause of local and referred muscle pain, as well as local inflammation in the muscle and fascia. From a clinical and sensory viewpoint, TrPs may be classified as active or latent. The principal difference is the reproduction of symptoms experienced by an individual (active) with or without stimulation. Local and referred pain elicited from latent TrPs may be transient in duration upon stimulation, and latent TrPs may be present without spontaneous symptoms. Both active and latent TrPs induce motor dysfunctions such as stiffness, restricted range of motion, and accelerated fatigability in the affected muscle. The interrater reliability of manual identification of latent TrPs in the calf muscles has been found to range from small to moderate. The clinical relevance of latent TrPs has increased in the last decade,4 and some studies have investigated the effects of treating them. Among all manual therapies targeted to latent TrPs, ischemic compression, or TrP pressure release, is the most commonly used. Although TrPs may affect any muscle, the gastrocnemius muscle may be the most susceptible in the lower extremity to developing them. It has been reported that 13% to 30% of the asymptomatic population has latent TrPs in these muscles, and their presence may affect sport practice. The purpose of this study will be to evaluate changes in neuromuscular function, pain perception, and basic physical properties in myofascial trigger points (TrPs) after a single treatment session of dry needling in the gastrocnemius muscle. A randomized within-participant clinical trial with a blinded assessor will be conducted. 50 asymptomatic volunteers (100 gastrocnemius-muscle) with MrPs gastrocnemius-muscle TrPs will bilaterally explored. Each extremity will be randomly assigned to the control group (no treatment) or the experimental group (60 seconds of dry needling over each TrP). Neuromuscular function of the gastrocnemius muscle will be assessed using a MyotonPro and a tensiomyography. Muscle flexibility will be analyzed using the lunge test and the passive ankle range of motion. The strength will be determined with a handheld dynamometer (MicroFET2). Pain perception will be analyzed with a 0-to-10 numerical pain rating scale and determination of pressure pain thresholds over each latent TrP.
Status | Completed |
Enrollment | 50 |
Est. completion date | July 6, 2021 |
Est. primary completion date | July 1, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - A TrP will be diagnosed using the following criteria: palpable taut band, presence of a painful spot in the taut band, and referred pain on palpation of the spot. Exclusion Criteria: - Participants were excluded if they reported any pain symptoms in the lower extremities in the previous year. - They were also excluded if they presented previous surgical interventions, previous lower-extremity injury, any underlying medical disease, pregnancy, or muscle soreness after vigorous exercise. |
Country | Name | City | State |
---|---|---|---|
Spain | Albert Pérez-Bellmunt | Sant Cugat del Vallès | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Universitat Internacional de Catalunya |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Neuromuscular Function (MyotonPro device) (Hz) | The Neuromuscular function will be assessed with a handheld MyotonPro myotonometry device, which will be placed on the skin, perpendicular to the surface of the belly of each gastrocnemius muscle, with the participant prone. The device will then lowered into the measurement position and held steady while it automatically conducted the predefined measurement series. The program consist of 3 single measurements with a recording interval of 1 second for each muscle. The average valuevfor each site will used in subsequent analyses. The reliability of the MyotonPro device has been reported to range from good to excellent (intraclass correlation coefficient = 0.8-0.93). | Change between baseline(immediately before intervention) and post intervention (immediately after intervention) | |
Primary | Tensomyography (m/s) | The Tensomyography evaluation will be done by using a Dc-Dc Trans-TekĀ® transductor (GK 40, Panoptik d.o.o., Ljubliana, Slovenia) that will be perpendicularly placed to the gastrocnemius belly. Two self-adhesive electrodes (TMG electrodes, TMG-BMC d.o.o., Ljubljana, Slovenia) will be placed equidistant, proximal (anode) and distal (cathode) to the sensor, with an inter-electrode distance of 5 cm. Patient will be placed in prone position with a foam Electrical stimulation was applied through a TMG-100 System electrostimulator (TMG-BMCd.o.o., Ljubljana, Slovenia). The amplitude will be progressively increased from 20 to 100 mA by 20 mA increments until there will be no further increase in maximal radial displacement or maximal stimulator output was reached (i.e 110mA) (20). Ten seconds rest will be given between the stimuli to minimize the effects of fatigue and potentiation. The meters per second of muscle contraction with the electrical stimulus will be measured. | Change between baseline(immediately before intervention) and post intervention (immediately after intervention) | |
Secondary | Pressure Pain Threshold (Kg/cm2) | The pressure pain threshold is the amount of pressure that is first perceived as painful. In this study, it will be assessed over the gastrocnemius TrP with a handheld mechanical pressure algometer (Trigger Plus, Pal- patronic, Hagen, Germany). Pressure will be applied at a rate of 10 N/cm2/s until the participant first reported a painful sensation. This procedure has shown good intrarater reliability. | Change between baseline(immediately before intervention) and post intervention (immediately after intervention) | |
Secondary | Pain with numerical pain rating scale | Participants will be also asked to rate their pain perception during the pressure pain threshold on an 11-point numerical pain rating scale (0 = no pain, 10 = maximum pain). | Change between baseline(immediately before intervention) and post intervention (immediately after intervention) | |
Secondary | Ankle Dorsiflexion Range of Motion (º) | Active ankle dorsiflexion range of motion will be assessed with the dorsiflexion lunge test. The test will be performed by placing the foot perpendicular to a wall and lunging the knee toward the wall. The foot will be moved further away from the wall until the maximum range of dorsiflexion was achieved. In order for the heel to not lift off of the floor, the examiner will place a band under the heel and applied tension.
The angulation from the tibia bone to the floor will be measured. The dorsiflexion lunge test has shown good intrarater and interrater reliability (intraclass correlation coefficient = 0.97). |
Change between baseline(immediately before intervention) and post intervention (immediately after intervention) | |
Secondary | Muscle Strentch (Newtons) | A dynamometer (MicroFET2, Hoggan Scientific, Salt Lake City, Utah) was used for isometric muscle-strength testing. All participants will barefoot during the testing procedure. Peak force will be measured by the dynamometer to the nearest 0.1 N. Contractions will be sustained for 3 seconds while the examiner applied unmoving resistance. Both gastrocnemius-testing will be repeated for 3 trials, with a 5-second rest between them. The mean of the 3 trials will be considered in the analysis. | Change between baseline(immediately before intervention) and post intervention (immediately after intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06029413 -
Myo vs. Myofascial Injection for Myofascial Trigger Points
|
N/A | |
Recruiting |
NCT04985578 -
Effects on Muscle Activity After Dry Needling in Myofascial Trigger Points of the Gastrocnemius Muscles
|
N/A | |
Completed |
NCT05546203 -
Trigger Point Treatment in Chronic Pelvic Pain
|
N/A | |
Completed |
NCT06258070 -
Clinical Performance of Therapeutic Use of BTX for Bruxism
|
N/A | |
Completed |
NCT04531306 -
An Analysis of Kinesio® Tape on Myofascial Pain Syndrome of the Iliotibial Band
|
N/A | |
Completed |
NCT03708107 -
Percutaneous Microelectrolysis (MEP) Versus Ischemic Compression in Miofascial Trigger Points
|
N/A | |
Completed |
NCT02913963 -
Changes on Pain and Range of Motion by the Use of Kinesio Taping in Subjects With Myofascial Trigger Point
|
N/A | |
Completed |
NCT02913976 -
Changes on Pain and Range of Motion by the Use of Kinesio Taping in Patients Diagnosed With Cervical Pain
|
N/A | |
Completed |
NCT04719689 -
Comparison of Dry Needling and Dry Cupping in Positional Fault of Pelvis
|
N/A | |
Recruiting |
NCT05792111 -
Caudal Epidural Steroid and Trigger Point Injection
|
Phase 4 | |
Completed |
NCT03704311 -
Evaluation of Mitochondrial Function in Myofascial Trigger Points Cohort Pilot Study Using High-resolution Respirometry
|
N/A | |
Recruiting |
NCT05429827 -
The Therapeutic Effects of Dextrose Injection for Myofascial Pain Syndrome
|
N/A | |
Recruiting |
NCT05151510 -
Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department
|
Phase 4 | |
Completed |
NCT05396196 -
An Analysis of Kinesio® Tape With Manual Fascial Glide Application on Trigger Points in The Iliotibial Band
|
N/A | |
Completed |
NCT05664165 -
The Efficiency of Dry Needling and Cold Spray-stretching Treatments
|
N/A | |
Completed |
NCT01250184 -
Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy.
|
Phase 4 | |
Enrolling by invitation |
NCT03941054 -
Myosfascial Trigger-Points and Effects on Neuromuscular Response
|
N/A | |
Completed |
NCT04993118 -
Integration of Neuromuscular Inhibition Technique On Trapezius Trigger Points.
|
N/A | |
Not yet recruiting |
NCT06338514 -
The Effectiveness of Dry Needling Treatment in Patients Diagnosed With Dorsal Myofascial Pain Syndrome.
|
N/A | |
Recruiting |
NCT06013644 -
Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome
|
Early Phase 1 |